Legislation has been introduced in the Texas Senate to require state health officials to study the use of MDMA, psilocybin, and ketamine as treatments for post-traumatic stress disorder (PTSD) and depression.

Dried psilocybin (left), MDMA (middle), and ketamine (right).
Senate Bill 3005 was filed yesterday with the exact language as House Bill 4014, which was introduced by State Representative John Bucy (R) last week.
The measure would direct the Department of State Health Services to conduct a comprehensive study on psychedelic-assisted therapy for PTSD, depression, and other related conditions. The research would be carried out in collaboration with Baylor College of Medicine and the Center for Psychedelic Research and Therapy at Dell Medical School at The University of Texas at Austin.
Continue reading